Skip to main content

Featured

Posted by

The Power of Color Psychology in Branding: What Does Your Brand Say Without Words?

When it comes to branding, first impressions are everything. Before a customer reads your tagline or explores your offerings, your brand's visual identity—especially color—does most of the talking. This is where color psychology becomes a powerful tool. Ask Yourself: What feeling do I want my brand to create? What colors align with that emotion? Are my current choices helping or hurting that intention? An effective brand identity silently communicates your message and values, long before you speak a single word. Let’s dive into the emotions different colors evoke, based on proven psychology. Color Psychology for Brands 1. Red Emotions: Love, Thrill, Awareness Best for: Creating urgency, excitement, or passion. Think Coca-Cola or Netflix. 2. Green Emotions: Peace, Growth, Harmony Best for: Eco-friendly, health-conscious, or nature-based brands like Whole Foods or Spotify. 3. Blue Emotions: Harmony, Trust, Consistency Best for: Tech, finance, and healthcare brands that need to build ...
Post a Comment
Read more
Labels
Posted by

Hearing may be end of road for breast cancer drug


WASHINGTON  The best-selling cancer drug in the world comes under federal scrutiny once again this week, as drugmaker Roche makes a last-ditch effort to keep Avastin approved for breast cancer, despite the government's opinion that it is ineffective against the disease.The two-day meeting at the Food and Drug Administration is unprecedented since the agency has already ruled against the drug, saying it neither extends nor improves life for breast cancer patients. Roche has taken the rare step of challenging government regulators.

Experts say the fact that the agency granted another hearing on the issue is testament to the difficulty of withdrawing approval of a cancer therapy."It says to me that either they've gotten a great deal of negative feedback from various quarters, or there's some kind of internal disagreement within the agency," said Dr. Gary Lyman, professor at the Duke Cancer Institute in North Carolina. Lyman was part of the majority of FDA advisers who voted 12-1 to revoke Avastin's approval last July.

Roche faces a smaller and even tougher panel this Tuesday: five out of six panelists voted against the drug last year. Only one voting member is new. The other panelists either couldn't make the hearing or were recused because of potential conflicts of interest. The FDA weighs the advice of its panels, though agency commissioner Margaret Hamburg will make the final decision.
Labels:

Comments

Post a Comment

Popular Posts